AAAlessandra Maciel Almeida

Alessandra Maciel Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alessandra Maciel Almeida has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pacientes com doença renal crônica estágio 3b: médicos generalistas e nefrologistas seguem as diretrizes da KDIGO?

    by Juliana Gazzi Macedo, Alessandra Maciel Almeida, Helady Sanders-Pinheiro, Raquel Aparecida Fabreti-Oliveira

    Resumo Introdução: O encaminhamento e o manejo adequados de pacientes com DRC da atenção primária à nefrologia são fundamentais para prevenir complicações e a progressão da doença. Objetivos: Descrever características demográficas e de acompanhamento de pacientes com DRC estágio 3b no momento do encaminhamento, o cuidado oferecido por generalistas e a assistência inicial por nefrologistas no Sistema Único de Saúde (SUS). Métodos: Coorte retrospectiva incluindo todos os pacientes com DRC estágio 3b na lista de espera para consulta nefrológica entre janeiro de 2018 e janeiro de 2020, em uma grande cidade do sudeste do Brasil. Foram avaliados dados sociodemográficos, comorbidades e adesão às recomendações de acompanhamento segundo Kidney Disease: Improving Global Outcomes (KDIGO) 2021. Os pedidos e resultados de exames laboratoriais foram comparados entre os períodos de atendimento pelo clínico geral e após consulta nefrológica. Resultados: Um total de 211 pacientes (idade média de 74 ± 12 anos) foram incluídos; 76% eram hipertensos e 46,9%, diabéticos. Cerca de metade realizou número adequado de consultas na atenção básica. O monitoramento laboratorial foi subótimo tanto na atenção primária quanto no cuidado especializado. Antes da nefrologia, exames de dosagem de hemoglobina e exames de urina estavam disponíveis em 32,2% e 19,4% dos pacientes, respectivamente. Após a consulta especializada, hemoglobina e potássio foram registrados para 68,3% e 58,8% dos pacientes, respectivamente. Conclusão: Embora os pacientes com DRC estágio 3b fossem acompanhados regularmente, a baixa adesão às recomendações de testes da KDIGO levanta preocupações quanto à adequação do cuidado. Fortalecer a comunicação e a implementação das diretrizes entre a atenção primária e os serviços de nefrologia é fundamental para aprimorar o manejo da DRC no âmbito do SUS.

  • Open Access

    Patients with chronic kidney disease stage 3b: do general practitioners and nephrologists follow KDIGO guidelines?

    by Juliana Gazzi Macedo, Alessandra Maciel Almeida, Helady Sanders-Pinheiro, Raquel Aparecida Fabreti-Oliveira

    Background: Appropriate referral and management of patients with chronic kidney disease (CKD) from primary care to nephrologists are essential to prevent disease progression and complications. Objectives: To describe the demographic and follow-up characteristics of patients with CKD stage 3b at the time of nephrology referral, the medical care offered by general practitioners, and the initial care provided by nephrologists in the Brazilian Unified Health System (SUS). Methods: This retrospective cohort study included all patients with CKD stage 3b on the waiting list for nephrology consultation between January 2018 and January 2020 in a large city in southern Brazil. Sociodemographic data, comorbidities, and adherence to follow-up recommendations based on the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines were analyzed. Laboratory test requests and results were compared between the periods of general practitioner care and the period following nephrology consultation. Results: A total of 211 patients (mean age 74 ± 12 years) were included; 76.0% were hypertensive and 46.9% had diabetes. Approximately half had an adequate number of primary care appointments. Laboratory monitoring was suboptimal in both primary and specialized care. Before nephrology consultation, hemoglobin and urinalysis were available for 32.2% and 19.4% of patients, respectively. After consultation, hemoglobin and potassium results were documented in 68.3% and 58.8% of patients, respectively. Conclusion: Although patients with CKD stage 3b were regularly followed, low adherence to KDIGO testing recommendations raises concerns about the adequacy of care. Strengthening communication and guideline implementation between primary care and nephrology services is crucial to improve CKD management within the SUS.


  • Open Access

    Primary care in supplementary health: assessment of costs in the care of older adult patients with heart diseases

    by Geórgia Silva Marques, Alessandra Maciel Almeida, Isabel Cristina Gomes, Michele Renata Barbosa da Silva, Bruno Almeida Rezende

    Objectives: to identify whether implementing a supplementary Primary Health Care (PHC) system makes it possible to reduce care costs for older adults with heart diseases. Methods: a retrospective cohort of 223 patients with heart disease aged ≥ 60 years. Data were obtained from medical records and cost databases, assessed for a period of one year before and after PHC implementation. The results were expressed as mean absolute frequencies for number of hospitalizations and as average annual expenses expressed in dollars (US$) in relation to cost data. Results: there was a reduction in hospitalization expenses after implementing supplementary PHC (p=0.01) and a decrease in the frequency of hospitalizations for the entire sample (p=0.006). There was a reduction in the frequency of consultations at the Emergency Room among frail older adults (p=0.011). Conclusions: there was a reduction in hospitalization costs and frequency of visits to the Emergency Room after supplementary PHC.


  • Open Access

    Atenção primária na saúde suplementar: avaliação de custos no cuidado de pacientes idosos com cardiopatias

    by Geórgia Silva Marques, Alessandra Maciel Almeida, Isabel Cristina Gomes, Michele Renata Barbosa da Silva, Bruno Almeida Rezende

    RESUMO Objetivos: identificar se a implementação de um sistema de Atenção Primária à Saúde (APS) suplementar possibilita a redução dos custos assistenciais de idosos com cardiopatias. Métodos: coorte retrospectiva de 223 pacientes cardiopatas com idade ≥ 60 anos. Os dados foram obtidos em registros médicos e banco de dados de custos, avaliados por período de um ano antes e após a implementação da APS. Os resultados foram expressos como media das frequências absolutas para número de internações e como gasto médio anual expressos em dólares (US$) em relação aos dados de custos. Resultados: houve redução nas despesas de internação após a implementação da APS suplementar (p=0,01) e diminuição da frequência de internação para toda a amostra (p=0,006). Houve redução na frequência de consultas no Pronto Atendimento entre os idosos frágeis (p=0,011). Conclusões: houve redução nos custos de internação e frequência de consulta no Pronto Atendimento após a APS suplementar.

  • Open Access

    First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

    by Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Adriana Maria Kakehasi, Alessandra Maciel Almeida, Pedro Ricardo Kömel Pimenta, Juliana Alvares-Teodoro, Francisco de Assis Acurcio

    BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple joints. It is associated with psoriasis and treated with synthetic and biologic drugs. OBJECTIVE: The objective of this study was to assess the outcomes of patients who received biologic thera-py with tumor necrosis factor (TNF) inhibitors in terms of effectiveness, safety, functionality, and quality of life. DESIGN AND SETTING: A prospective observational study was performed at a single center in Belo Hor-izonte, Brazil. METHODS: Patients with PsA who received their first TNF inhibitor treatment were followed up for 12 months. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BAS-DAI) and Clinical Disease Activity Index (CDAI). Functionality was measured using the Health Questionnaire Assessment (HAQ), and quality of life was evaluated using the European Quality of Life Five Dimensions (EQ-5D). Multiple linear regression was used to identify predictors of the clinical response at 12 months. RESULTS: A total of 143 patients treated with adalimumab or etanercept were evaluated. Most of the clinical measures were significantly improved at 12 months. However, 31%-51% of the patients did not achieve good clinical control. No differences were observed between adalimumab and etanercept, ex-cept for poor functionality at 12 months among patients treated with etanercept. The main predictors of a worse clinical response were female sex, etanercept use, poor functionality, or lower quality of life at baseline. The main adverse reactions were alopecia, headache, injection site reaction, sinusitis, flu, dyslip-idemia, and infections. CONCLUSION: TNF inhibitor therapy was effective and safe. However, despite improvements in clinical measures, most patients did not achieve satisfactory control of the disease.


  • Open Access

    Biological therapy in psoriatic arthritis patients with and without previous biologic experience

    by Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Adriana Maria Kakehasi, Alessandra Maciel Almeida, Juliana Alvares-Teodoro, Francisco de Assis Acurcio

    Objective: this study evaluated the biological therapy effects on disease activity, functionality, quality of life, drug survival, and safety of patients with psoriatic arthritis naïve and experienced in biological therapy. Methods: a oneyear prospective observational study was performed. The outcomes assessed were drug survival, disease activity, functionality, quality of life, and safety. Multiple linear regression was used to assess predictive factors for clinical response.Results: a total of 205 patients were included, 155 of whom were biologic naïve and 50 biologic experienced. Drug survival rate was greater for naïve patients than experienced patients at 6 months, but not at 12 months. Drug survival rates were 71.5% for naïve patients and 70.0% for experienced patients at 12 months. All clinical parameters improved for both biologic naïve and experienced patients. At 12 months, 63% of naïve patients and 52% of experienced patients had an improvement in their quality of life. Besides, 48% of naïve patients and 42% of experienced patients had an improvement in functionality. The axial disease improved in 67% of naïve individuals and 56% of experienced patients. Good control of peripheral disease was achieved by 49% of naïve patients and 44% of experiencedpatients. Female sex, use of etanercept or infliximab, and lower functionality or quality of life at baseline were the main predictors of poor clinical response. Conclusion: Patients’ health improved after starting biological therapy. In general, biologic experienced patients had more adverse reactions and lesser effectiveness.

  • Open Access

    Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System

    by Elisa Neide Barbosa de Souza, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Edna Afonso Reis, Juliana Alvares-Teodoro, Francisco de Assis Acurcio, Alessandra Maciel Almeida

    Objective To evaluate the therapeutic response (functionality) and its associated factors in patients on biological drugs on the Public Health System for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Methods An open prospective cohort was carried out from 2011 to 2019, in Belo Horizonte (MG). Functionality was assessed using the Health Assessment Questionnaire Disability-Index at baseline, and after 6 and 12 months of follow-up. Factors associated with poor functionality were identified through logistic regression. Results The median


  • Open Access

    A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications

    by Paulo H.R.F. Almeida, Brian Godman, Vania dos Santos Nunes-Nogueira, Lívia L.P. de Lemos, Francisco de Assis Acúrcio, Augusto A. Guerra-Junior, Vânia E. de Araújo, Alessandra M. Almeida, Juliana Alvares-Teodoro

    This article describes a cross-sectional study involving 401 adults with type 1 diabetes treated with insulin glargine in Minas Gerais, Brazil. Health-related quality of life was assessed, and worse scores were found to be associated with a low level of education, self-perceived health reported as poor/very poor, being bedridden and not physically exercised, having seen a doctor more than four times in the past year, and having reported comorbidities and episodes of hypoglycemia.


  • Open Access

    The increasing burden of pancreatic cancer in Brazil from 2000 to 2019: estimates from the Global Burden of Disease Study 2019.

    by Diogo Oliveira Chaves, Aline Cândida Bastos, Alessandra Maciel Almeida, Maximiliano Ribeiro Guerra, Maria Teresa Bustamante Teixeira, Ana Paula Souto Melo, Valéria Maria de Azeredo Passos

    Pancreatic cancer is increasing worldwide. The burden of pancreatic cancer in Brazil and its states was analyzed and compared with that from the USA and China. This is a descriptive study of the incidence and mortality estimates from the Global Burden of Disease 2019 study, from 2000 to 2019. The Brazilian states presenting the highest and lowest socio-demographic index (SDI) were selected from each of the five regions. The SDI consists of the per capita income, education, and fertility rate of each population. A significant increase was found in age-standardized incidence and mortality of pancreatic cancer in all three countries, with differences in magnitude and annual increases. In Brazil, this incidence rose from 5.33 [95% Uncertainty Interval (UI): 5.06- 5.51] to 6.16 (95% UI: 5.68- 6.53) per 100,000 inhabitants. China and the Brazilian states with the lowest SDI, such as Pará and Maranhão, showed lower incidence and mortality rates, although presenting the highest annual increases. No difference was found between the sexes. A higher mortality rate was observed for those individuals of 70+ years, which was three to four times higher than those aged 50 to 69 years. The increasing burden of pancreatic cancer in the studied countries, and the higher estimates for the elderly in a fast-aging country such as Brazil, indicates that more resources and health policies will be necessary. The greatest increase in the states with lower SDI reflects inequalities in the access to diagnosis and registries of this cancer.


  • A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications

    by Paulo H R F Almeida, Brian Godman, Lívia L P de Lemos, Thales B C Silva, Francisco De Assis Acúrcio, Augusto Afonso Guerra‑Junior, Vânia E De Araújo, Alessandra M Almeida, Juliana Alvares-Teodoro

    Objectives: The study aim was to identify key factors associated with the health-related quality of life (HRQOL) of patients with type 1 diabetes mellitus (T1DM) treated with neutral protamine Hagedorn (NPH) insulin or human insulin analog glargine (IGLA). Methods: We conducted two cross-sectional studies in Minas Gerais State, Brazil. One with 401 patients treated with IGLA, and the other with 179 T1DM patients treated with NPH. HRQOL was measured by Euroqol (EQ-5D-3L). Key findings: Most participants were male (51%), aged between 18 and 40 years (47%), non-black (58%) and from the highest economic strata (A1-B2) (74%). Participants perceived their health as good/very good (51%), had one to three medical consultations in the previous year (51%), were not hospitalized in the previous year (74%), did not report angina (96%), diabetic neuropathy (90%), hearing loss (94%) or kidney disease (89%). Non-severe hypoglycaemia episodes in the last 30 days were reported by 17% of participants. Conclusions: Higher HRQOL was associated with younger age (18–40 years), good/very good health self-perception, having had up to three medical consultations in the last year, not being hospitalized in the last year, having none to three comorbidities, not reporting angina, diabetic neuropathy, hearing loss or kidney disease and having had episodes of non-severe hypoglycaemia. In addition, the findings of our study demonstrated inequalities in access to treatment, which will be the subject of future research projects.